Arakawa S, Maeda H, Fujii A, Kamidono S, Hamada K, Miyazaki S, Hara S
Department of Urology, Kobe University, School of Medicine.
Hinyokika Kiyo. 1989 Apr;35(4):697-704.
In vitro studies of elimination of arbekacin (HBK), a new aminoglycoside antibiotic, from blood by means of hemodialysis or adsorption with charcoal, and pharmacokinetic studies in patients with renal dysfunction were examined. HBK was well eliminated by hollow fiber type artificial kidney (HFAK) with a half-life of 0.13 hr. HBK was also well eliminated by an adsorption tube containing charcoal with even shorter half-life of 0.03 hr. As to pharmacokinetics of HBK in patients with renal dysfunction, blood levels became higher with a greater reduction in 24 hr endogenous creatinine clearance (Ccr). A decreasing tendency was also seen in urinary recovery rate. These results indicated that hemodialysis and adsorption with charcoal are useful for elimination of HBK from blood. It is recommendable in patients with renal dysfunction to take some measures such as prolongation of administration interval of HBK according to the extent of decrease in Ccr.
对新型氨基糖苷类抗生素阿贝卡星（HBK）通过血液透析或用活性炭吸附从血液中消除的体外研究，以及对肾功能不全患者的药代动力学研究进行了考察。中空纤维型人工肾（HFAK）能很好地消除HBK，半衰期为0.13小时。含活性炭的吸附管也能很好地消除HBK，半衰期更短，为0.03小时。至于HBK在肾功能不全患者中的药代动力学，随着24小时内生肌酐清除率（Ccr）更大程度的降低，血药浓度会升高。尿回收率也呈下降趋势。这些结果表明，血液透析和用活性炭吸附对从血液中消除HBK是有用的。对于肾功能不全患者，建议根据Ccr降低的程度采取一些措施，如延长HBK的给药间隔。
